Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.38 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18519079 | 0.91 | LMNA (0.39) | LMNASPR | |
| SCHEMBL5552443 | 0.89 | MAP2K1 (0.52) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL2720014 | 0.89 | MAP2K1 (0.38) | MAP2K1MAP2K2LMNAMAP2K5EIF2AK1 | |
| SCHEMBL21132542 | 0.85 | MAP2K1 (0.44) | MAP2K1MAP2K2LMNAMAP2K5EIF2AK1 | |
| SCHEMBL18518807 | 0.85 | MAP2K1 (0.34) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL5556998 | 0.84 | MAP2K1 (0.55) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL5557918 | 0.84 | MAP2K1 (0.44) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL18518884 | 0.82 | MAP2K1 (0.35) | MAP2K1MAP2K2LMNAMAP2K5EIF2AK1 | |
| SCHEMBL18518641 | 0.81 | MAP2K1 (0.42) | MAP2K1MAP2K2LMNAMAP2K5EIF2AK1 | |
| SCHEMBL16322852 | 0.81 | MAP2K1 (0.49) | MAP2K1MAP2K2MAP2K5EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635587-B1 | 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| WO-2012059041-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | MAP3K6, MAP3K1, MAP3K21 | MAP2K1 44/4885MAP2K2 45/4885LMNA 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.